Free Trial
NASDAQ:PDEX

Pro-Dex (PDEX) Stock Price, News & Analysis

Pro-Dex logo
$52.87 +1.97 (+3.87%)
Closing price 04:00 PM Eastern
Extended Trading
$56.28 +3.41 (+6.46%)
As of 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Pro-Dex Stock (NASDAQ:PDEX)

Key Stats

Today's Range
$46.80
$55.51
50-Day Range
$32.00
$55.19
52-Week Range
$16.84
$59.60
Volume
98,006 shs
Average Volume
23,321 shs
Market Capitalization
$172.41 million
P/E Ratio
26.30
Dividend Yield
N/A
Price Target
$52.00
Consensus Rating
Buy

Company Overview

Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.

Remove Ads

Pro-Dex Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
27th Percentile Overall Score

PDEX MarketRank™: 

Pro-Dex scored higher than 27% of companies evaluated by MarketBeat, and ranked 773rd out of 901 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Pro-Dex has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Pro-Dex has received no research coverage in the past 90 days.

  • Read more about Pro-Dex's stock forecast and price target.
  • Earnings Growth

    Earnings for Pro-Dex are expected to grow by 3.00% in the coming year, from $2.00 to $2.06 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pro-Dex is 26.30, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 20.63.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pro-Dex is 26.30, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.79.

  • Price to Book Value per Share Ratio

    Pro-Dex has a P/B Ratio of 5.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Pro-Dex's valuation and earnings.
  • Percentage of Shares Shorted

    2.16% of the float of Pro-Dex has been sold short.
  • Short Interest Ratio / Days to Cover

    Pro-Dex has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pro-Dex has recently increased by 166.27%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Pro-Dex does not currently pay a dividend.

  • Dividend Growth

    Pro-Dex does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.16% of the float of Pro-Dex has been sold short.
  • Short Interest Ratio / Days to Cover

    Pro-Dex has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pro-Dex has recently increased by 166.27%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Pro-Dex has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Pro-Dex this week, compared to 1 article on an average week.
  • Search Interest

    3 people have searched for PDEX on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Pro-Dex to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pro-Dex insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,270,494.00 in company stock.

  • Percentage Held by Insiders

    47.50% of the stock of Pro-Dex is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 15.28% of the stock of Pro-Dex is held by institutions.

  • Read more about Pro-Dex's insider trading history.
Receive PDEX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pro-Dex and its competitors with MarketBeat's FREE daily newsletter.

PDEX Stock News Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
See More Headlines

PDEX Stock Analysis - Frequently Asked Questions

Pro-Dex's stock was trading at $46.75 on January 1st, 2025. Since then, PDEX shares have increased by 13.1% and is now trading at $52.87.
View the best growth stocks for 2025 here
.

Pro-Dex, Inc. (NASDAQ:PDEX) announced its quarterly earnings results on Thursday, January, 30th. The medical instruments supplier reported $0.61 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.23. Pro-Dex had a trailing twelve-month return on equity of 21.68% and a net margin of 11.06%.

Shares of PDEX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pro-Dex investors own include NVIDIA (NVDA), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE), ServiceNow (NOW), Arista Networks (ANET) and Jabil (JBL).

Company Calendar

Last Earnings
1/30/2025
Today
4/07/2025
Next Earnings (Estimated)
5/01/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:PDEX
Employees
140
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$52.00
High Stock Price Target
$52.00
Low Stock Price Target
$52.00
Potential Upside/Downside
-2.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
26.86
Forward P/E Ratio
26.59
P/E Growth
N/A
Net Income
$2.13 million
Pretax Margin
14.34%

Debt

Sales & Book Value

Annual Sales
$61.00 million
Cash Flow
$1.53 per share
Price / Cash Flow
34.81
Book Value
$9.76 per share
Price / Book
5.45

Miscellaneous

Free Float
1,712,000
Market Cap
$173.39 million
Optionable
Not Optionable
Beta
0.40

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:PDEX) was last updated on 4/7/2025 by MarketBeat.com Staff
From Our Partners